First-in-human study of first-in-class fatty acid synthase inhibitor, TVB-2640 - European Medical Journal

Continue

First-in-human study of first-in-class fatty acid synthase inhibitor, TVB-2640

Oncology
At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses a first-in-human study of the first-in-class fatty acid synthase inhibitor, TVB-2640, as monotherapy or in combination for the treatment of patients with solid malignancies.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.